

## Memory impairment and latent toxoplasmosis; association, awareness and risk factors in a high Toxoplasma-seroprevalence community

Shirzad Fallahi <sup>1-2</sup> , Nozhat Zebardast <sup>3</sup> , Seyedeh Fatemeh Moosavi <sup>2</sup>, Farnaz Kheirandish <sup>1-2\*</sup> 

<sup>1</sup>. Hepatitis Research Center, Lorestan University of Medical Science, Khorramabad, Iran.

<sup>2</sup>. Department of Medical Parasitology and Mycology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.

<sup>3</sup>. Cellular and Molecular Research Center, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran.

### Article Info

**Article type:**  
Research Article

**Received:**  
7 January 2021

**Revised:**  
24 February 2021

**Accepted:**  
20 March 2021

### ABSTRACT

**Background and Objective:** Memory impairment (MI), happens when a person loses the ability to remember information and events they would normally be able to recall. Toxoplasmosis is one of the most important parasitic diseases involving the brain. Due to the localization of *Toxoplasma gondii* tissue cysts in brain and some related reports, the effect of toxoplasma on neurodegenerative diseases has been suggested.

**Methods:** The present study was conducted to investigate the probable association between MI and toxoplasmosis using serological and molecular techniques. The study population consisted of 87 Alzheimer's patients (AP) and 87 healthy controls which were selected under the supervision of neurology consultant. The *Toxoplasma*-specific antibodies were measured using commercial ELISA kits. The desired region for *Toxoplasma* B1 gene was amplified by using specific primers and a thermocycler. Specificity of primers was confirmed by direct sequencing, aligning and phylogenetic analysis of the amplicons.

**Findings:** Prevalence of toxoplasmosis in AP and control group was 66.6% and 56.3% ( $P=0.99$ ) and 52.8% and 40.2% ( $P=0.229$ ) using ELISA and PCR respectively. Despite the higher prevalence of toxoplasmosis in AP compared with the controls, a significant relationship was not found between MI and toxoplasmosis. The multiple sequence alignment of *T. gondii* isolates revealed a common haplotype. The significant relationship between some variables and toxoplasmosis as well as the MI could reveal the risk factors for MI.

**Conclusion:** These results provide fresh insights into the ambiguous association between *T. gondii* infection and MI. As a probable or concomitant risk factor, toxoplasmosis could induce the MI, principally in patients with the chronic or latent infection.

**Keywords:** Memory Impairment, Probable link, Seromolecular, Toxoplasmosis

**Cite this article:** Fallahi, et al. Memory impairment and latent toxoplasmosis; association, awareness and risk factors in a high Toxoplasma-seroprevalence community. *Current Research in Medical Sciences*. 2021; 5(1):43-51.



© The Author(s).

Publisher: Babol University of Medical Sciences

**\*Corresponding Author:** Farnaz Kheirandish, Associate professor of Medical Parasitology. ORCID: 0000-0003-2680-0703  
**Address:** Department of Medical Parasitology and Mycology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.  
**E-mail:** kheirandish.f@lums.ac.ir, Kheirandish81@yahoo.com

## Introduction

Alzheimer's disease is the most common form of dementia, a general term for memory impairment (MI) and other intellectual abilities serious enough to interfere with daily life which has risen in prevalence to an estimated 20-30 million people worldwide [1,2]. MI or amnesia, happens when a person loses the ability to remember information and events they would normally be able to recall. The memory loss accounts for 60 to 80 percent of dementia cases [2,3]. MI, is defined as a debilitating neurodegenerative disorder characterized by the progressive loss of cholinergic neurons, leading to the onset of severe behavioral, cognitive and motor impairments [4]. It is estimated that 30–50% of patients with Alzheimer's disease have comorbid depression [5]. Various mediators releasing from microglial cells such as cytokines, reactive oxygen species, complement factors, neurotoxic secretory products, and free radicals also augment inflammatory responses and many of these mediators are known to stimulate amyloid precursor protein deposition and contribute to neuronal death in MI [4,5]. One of the early symptoms of MI is the gradual impaired memory, especially spatial memory in which reducing the amount of acetylcholine as a result of releasing more acetyl cholinesterase enzyme can disrupt spatial memory. Different studies have shown that transfer of oxygen to the brain and decreased blood flow may act as a mechanism in the complex etiology of Alzheimer's disease [3,5,6].

*Toxoplasma gondii* is a neurotropic obligate intracellular protozoan that causes the toxoplasmosis, one of the most important parasitic diseases involving the brain. Found worldwide, *T. gondii* is capable of infecting virtually all warm-blooded animals [7,8]. In areas where people consume raw or undercooked meat containing the tissue cyst of parasite and cats as the definitive host, live close to human, the rate of infection is higher [9]. Different reports showed that chronic *Toxoplasma* infection may alter the human behavior and affect the memory [10,11]. Behavioral changes and/or memory impairment attributed to *Toxoplasma* infection may have been due to the nerve damage caused by parasitic infection [6,10]. Biosynthesis of dopamine and/or serotonin can be directly affected by the aromatic amino acid, hydroxylases in *T. gondii* genome. The missing link between toxoplasmosis and mental disorders can be associated with increasing of dopamine in the brains of infected patients [11]. Serology testing of the *T. gondii*-specific antibodies is the mainly limited method to assess the possible relationship between neurodegenerative diseases and *T. gondii* infection. Therefore, the present study was conducted to evaluate the probable association between MI and *T. gondii* infection in a population with high *Toxoplasma* seroprevalence by using both the serology (ELISA) and molecular (PCR) techniques.

## Methods

### *Study population and clinical samples*

The study population consisted of 174 Alzheimer's patients (AP) and healthy controls (87 people in each group) that were selected under the supervision of a neurologist during a six-month period. The inclusion and the exclusion criteria were according to the mental status of APs and level of MI (mild, moderate, and advanced) which were determined by neurology consultant based on the associated factors such as navigation, remind, and construction. According to the above-mentioned criteria, evidence and medical records, the control group should have no neuropsychological problems. As much as possible, it was tried that the two case and group control groups be matched in terms of the residency, age and sex variables. At first, all participants signed a satisfaction form and then completed a standard clinical questionnaire

containing information about symptoms of MI and demographic characteristics. Whole blood samples were taken from each participant with and without EDTA and serum and buffy coat specimens were separated and stored at  $-20^{\circ}\text{C}$  until use.

### ***Serology assessment***

The anti-*T. gondii* specific IgG and IgM antibodies were measured by enzyme-linked immunosorbent assay (ELISA) test using commercial kits (Pishtazteb Co, Iran) based on the manufacturer instructions. In the case of borderline test results, an additional sample was taken 7 days later and retested in parallel with the first patient sample.

### ***Molecular evaluation***

PCR assay was performed in duplicate using the primer pair targeting the 35-fold-repetitive B1 gene of *T. gondii*<sup>12</sup>. The PCR reaction was performed in a final volume of 20  $\mu\text{l}$  using the *Taq DNA Pol* 2.0  $\times$  master mix (Cinna Gen, Iran) contained 10 mM Tris-HCl, pH 8.3 (at  $25^{\circ}\text{C}$ ), 50 mM KCl, 1.5 mM  $\text{MgCl}_2$ , 5  $\mu\text{M}$  each primer (Bioneer, Korea), 250  $\mu\text{M}$  each dNTP, 0.1 U *Taq DNA* polymerase and 100 ng/ $\mu\text{L}$  (1  $\mu\text{l}$ ) of extracted DNA. Reaction was conducted in a Thermal Cycler (BIO RML, USA) with an initial denaturation at  $94^{\circ}\text{C}$  for 5 min followed by 35 cycles of denaturation at  $94^{\circ}\text{C}$  for 20 s, annealing at  $47^{\circ}\text{C}$  for 20 s and finally an extension step at  $72^{\circ}\text{C}$  for 20 s followed by a 5 min final extension at  $72^{\circ}\text{C}$ . A PCR negative-control sample omitted template DNA, which was replaced by sterile water and a positive-control sample that used extracted DNA from *T. gondii* tachyzoites RH-strain. The PCR products were electrophoresed in a 2% TAE (Tris-acetate-EDTA) agarose gel and stained with the ethidium bromide solution (1  $\mu\text{g}/\text{ML}$ ). The PCR amplification is expected to yield a 194 bp product for B1 positive reaction. To confirm the specificity of primers for the *T. gondii* detection, the purified PCR product was sequenced. The MegAlign program from Laser Gene Bio Computing Software Package (DNASTAR, Madison, WI) was used to construct the distance matrix among isolates sequenced and the other reported isolates. The phylogenetic tree was constructed based on maximum likelihood algorithm with kimura 2-parameter model inferred by MEGA5.05 software to demonstrate the status of analyzed sequences. The 1000 bootstrap re-sampling was conducted to evaluate the accuracy of phylogenetic tree.

### ***Statistical analysis***

The data was analyzed using SPSS 18 software (SPSS, Chicago, IL, USA) and the Multivariate logistic regression, Chi-square and Fisher's exact tests. The odds ratios (OR) and 95% confidence intervals (CI) after adjustments were used to assessment the associations. For differences, a *P value* of  $< 0.05$  was considered statistically significant.

## **Results**

### ***Demographic characteristics and serology status***

Demographic characteristics of the participants in terms of MI are shown in Table 1. Various titers of *Toxoplasma*-IgG antibody which shows the chronic phase of toxoplasma infection, were found in 107 people. In other words, the seroprevalence of *T. gondii* IgG antibody in patients with Alzheimer's disease and the control group was obtained 66/6% (58/87) and 56/32% (49/87) respectively. The *Toxoplasma*-IgM antibody that related to acute phase of the disease, was not found in the subjects. The rate of *T. gondii* infection in piped water consumers, with a mixed diet, residents of the city, older than 60 years, and

illiterates was significantly higher than other groups ( $P<0.05$ ) (Table 1). According to Chi-square and Multivariate logistic regression tests, with all other variables assumed constant, there was not a significant relationship between results of serology test and MI ( $P=0.926$ ) (Table 2). In the present study in terms of stages of MI, 17.2%, 12.6% and 70.1% of patients were in the mild, moderate and advanced stages of MI respectively.

Variable	ELISA		P value	PCR		P value
	Positive N (%)	Negative N (%)		Positive N (%)	Negative N (%)	
Age						
(Mean ± SD)	65 ± 20.3	56.92 ± 23.1	0.016	64 ± 22.3	60 ± 21.12	0.22
Sex						
Male	38 (21.8)	28 (16.1)	0.43	35 (20.1)	31 (17.8)	0.21
Female	69 (39.7)	39 (22.4)		46 (26.4)	62 (35.6)	
Residency						
City	54 (31.0)	57 (32.8)	< 0.001	23 (13.2)	88 (50.6)	<0.001
Village	53 (30.5)	10 (5.7)		58 (33.3)	5 (2.9)	
Level of education						
Illiterate	64 (36.8)	30 (17.2)	0.005	50 (28.7)	44 (25.3)	0.037
Elementary	27 (15.5)	12 (6.9)		14 (8.0)	25 (14.4)	
Cycle	6 (3.4)	6 (3.4)		9 (11.1)	3 (1.7)	
Diploma	8 (4.6)	9 (5.2)		8 (9.9)	9 (5.2)	
Advanced Diploma	0 (0.0)	2 (1.1)		0 (0.0)	2 (1.1)	
Bachelor	2 (1.1)	8 (4.6)		0 (0.0)	10 (5.7)	
Diet type						
Most vegetables	0 (0.0)	0 (0.0)	0.010	12 (6.9)	2 (1.1)	0.004
Most protein	13 (7.5)	1 (0.6)		69 (39.7)	91 (52.3)	
A mixture of both	94 (54.0)	66 (37.9)		0 (0.0)	0 (0.0)	
Type of water consumed						
Piping	93 (53.4)	67 (38.5)	0.001	67 (38.5)	93 (53.5)	<0.001
Well	14 (8.0)	0 (0.0)		14 (8.0)	0 (0.0)	

**Table 1.** Sociodemographic variables of participants in the study based on infection with *T. gondii*.

### Molecular evaluation

The results of PCR assay indicated that 46 (52.8%) of AP and 35 (40.2%) of control subjects are positive for the *T. gondii* DNA (Fig. 1). Based on analysis of the data by Chi-square and Multivariate logistic regression tests with all other variables assumed constant there was not a significant relationship between

the results of PCR assay and MI ( $P=0.226$ ) (Table 2). While, there was a significant relationship between the results of PCR test and diet type ( $P=0.004$ ) and residency ( $P<0.001$ ) according to data analysis by *Chi-Square* tests (Table 1).

According to the multiple sequence alignment of the purified PCR products it was found that the obtained partial sequences were similar to the corresponding sequences of B1 gene reported in GenBank (common haplotype; Accession No., AF179871), which proved that the PCR primers of the B1 genomic target are highly specific for the detection of *T. gondii*. The current identified *T. gondii* isolates (Park1\*-Park 4\*) had a percent identity (93.6-100%) and divergence (0-6.7%) with other sequences from Slovakia, Brazil, India and Southwest of Iran. The status and topology of identified *T. gondii* isolates with bootstrap values higher than 70% were supported in their specific complex by conducting Phylogenetic analyses.

Variable	Group	Odds ratio (OR)	Confidence interval (CI, 95 %)	P. value
Age	-	1.2	(1.13-1.27)	0.001<
Sex	Male	Reference		-
	Female	3.41	(1.13-10.3)	0.036
Type of water consumed	Well	Reference	-	-
	Piping	1.41	(0.19-10.2)	0.734
Result of serology test	Negative	Reference	-	-
	Positive	0.92	(0.30-2.85)	0.926
Result of molecular test	Negative	Reference	-	-

**Table 2.** Influence of age, sex, type of water consumed and result of serology and molecular tests on memory impairment by multivariate logistic regression.

## Discussion

Toxoplasmosis is a zoonotic parasitic disease that can be transmitted to humans through various routes such as; food, water or soil contaminated with oocysts, raw or undercooked meat containing tissue cyst, transplacental transmission, blood transfusion and organ transplantation<sup>7,12</sup>. Throughout the acute stage of disease tachyzoites, the rapidly divided form of parasite disseminated via the lymphatic system or blood to different organs, causing toxoplasmosis, which is characterized by hyperplasia of the reticular cells and lymphadenopathy. However, the brain is the most commonly affected organ during the chronic, latent infection of toxoplasmosis [7,13]. In this regard, different epidemiological evidences indicate the probability of an association between exposures to *T. gondii* and increased the risk of neurodegenerative

disorders. Additionally, the genetics and neurobiology studies of *T. gondii* unraveled the evolutionary mechanisms by which parasite replication within the brain can alter behavior in mammals, thus providing a theoretical framework for the relationship between toxoplasmosis and neurological disease in humans [11,14,15].

In the present study, serological and molecular assessments of the participants revealed the higher prevalence of *T. gondii* infection in AP compared to the control group. In a study conducted by Kusbeci et al. [16] patients with Alzheimer showed significantly higher titers in seropositivity than healthy controls (44.1% versus 24.3%). The possible association between *Toxoplasma* infection and Parkinson disease (PD) was investigated by Miman and colleagues<sup>15</sup> by evaluating the anti-*T. gondii* IgG antibodies. The seroprevalence rate of toxoplasmosis in patients with PD and control groups were 42.3% and 22.5%, respectively, and they were statistically significant ( $P=0.006$ ). In another case-control study, the presence of *T. gondii* IgG and IgM antibodies were examined in 50 schizophrenic patients and 150 control subjects using ELISA, in which both the seroprevalence and the level of *T. gondii* IgG antibodies were higher in schizophrenic patients (20%) than in control subjects (5.3%) ( $P=0.003$ ) [17]. Likewise, in the two other studies, seropositivity rate for anti-*T. gondii* IgG antibodies was found to be significantly more in patients with obsessive-compulsive disorder (OCD) and PD compared to the control groups [15]. Consequently, the authors concluded that toxoplasmosis may be involved in the complex mechanisms of psychiatric illness and neurodegenerative disorders. However, the anti-*T. gondii* IgG titers showed IgG levels examined at the same time, and thus, do not indicate a causal relationship between *T. gondii* infection and the etiology of neurodegenerative disorders. Since the causal relationship between *T. gondii* infection and the etiology of psychiatric disorders can be determined by conducting more sensitive and specific tests under known conditions along with information on times between disease onset and infection [18,19].

Assuming constant consideration of other variables, based on the Chi-Square test, the probability of developing Alzheimer's disease in people with toxoplasmosis was almost twice as high as that of healthy subjects, which the relationship was not statistically significant. Despite the indirect relationship, the result suggests that toxoplasma infection can be considered as an important risk factor for MI. With of all other variables assumed constant, for each unit increase in the age, the chance of developing MI increased 19% and 20% by serological and molecular assays respectively that this increases were significant (Table 2). El-Sahn and colleagues<sup>18</sup> reported that the *Toxoplasma* infection increased with age in both schizophrenia and healthy control groups and there isn't a significant association with sex. In the present study, there was a significant relationship between age, sex, location and types of food variables with the *Toxoplasma* infection among the two cases and control groups which can be considered as risk factors for MI. In this study, there was a statistically significant association between the symptoms of mood change (anger), incontinence and forgetfulness with the results of serology and molecular tests that represent the possible relationship between behavioral changes with *T. gondii* infection. In terms of the impact of toxoplasmosis on personality, infected men seemed more jealous, less confident, more dogmatic, less impulsive, more orderly and more cautious than others. Conversely, infected women appeared to be warmest, more insecure, more sanctimonious, more persistent and more conscientious than others which these behavioral differences between *Toxoplasma*-infected and healthy subjects may be due to differences in the level of testosterone [11]. In the current study, no new haplotype was found among the analyzed sequences of *Toxoplasma* B1 gene. The small effective sample size, short length of the amplified B1 gene sequence (194 bp) and to be conserved the nature of B1 gene may be effective in this issue. The low number of patients, a wide age range of participants and lack of cooperation of all patients, were the limitations of the study.

## Conclusion

The results of the study provide fresh insights into the ambiguous association between *T. gondii* infection and MI. As a probable or concomitant risk factor, toxoplasmosis could induce the MI, principally in patients with the chronic or latent infection.

## Acknowledgment

The authors thank all clinicians, psychiatrists, psychologists, nurses and study population involved in the study.

## ORCID iD

Shirzad Fallahi <https://orcid.org/0000-0003-1826-7910>

Nozhat Zebardast <https://orcid.org/0000-0003-3791-9312>

Farnaz Kheirandish <https://orcid.org/0000-0003-2680-0703>



## References

1. Selkoe, D., J. and Hardy J., The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med.*, 2016, 8, 595-608.
2. Kaminsky, Y., G., Reddy, V., P., Ashraf, G., M., Ahmad, A., Benberin, V., V., Kosenko, E., A. and Aliev, G., Age-Related Defects in Erythrocyte 2,3-Diphosphoglycerate Metabolism in Dementia. *Aging Dis.*, 2013, 4, 244-255.
3. Allinquant, B., Clamagirand, C. and Potier, M., C., Role of cholesterol metabolism in the pathogenesis of Alzheimer's disease. *Curr Opin Clin Nutr Metab Care.*, 2014, 17, 319-323.
4. Godoy, J., A., Rios, J., A., Zolezzi, J., M., Braidy, N., and Inestrosa N., C. Signaling pathway cross talk in Alzheimer's disease. *Cell Communicat Signal.*, 2014, 12, 23.
5. E Lakhan Sh., Alzheimer Disease Differential Diagnoses. *DDX.*, 2017, 7, 26.  
<http://emedicine.medscape.com/article/1134817-differential>.
6. Hermes, G., Ajioka, J., W., Kelly, K., A., Mui, E., Roberts, F., Kasza, K., Mayr, T., Kirisits, M., J., Wollmann. R., Ferguson, D., J., Roberts, C., W., Hwang, J., H., Trendler, T., Kennan, R., P., Suzuki, Y., Reardon, C., Hickey, W., F., Chen, L. and McLeod, R., Neurological and behavioral abnormalities, ventricular dilatation, altered cellular functions, inflammation, and neuronal injury in brains of mice due to common, persistent, parasitic infection. *J. Neuroinflammat.*, 2008, 5, 48.
7. Montoya, J., G. and Liesenfeld, O., Toxoplasmosis. *Lancet*, 2004, 363, 1965–1976.
8. Fallahi, Sh., Arab-Mazar, Z., Ghasemian, M. and Haghighi, A., Challenging loop-mediated isothermal amplification (LAMP) technique for molecular detection of *Toxoplasma gondii*. *Asian Pacific J. Trop. Med.*, 2015, 3, 366-372.
9. Jones, J., L., Ogunmodede, F., Schftel, J., Kirkland, E., Lopez, A., Schulkin, J. and Lynfield, R., Toxoplasmosis-related knowledge and practices among pregnant women in the United States. *Infect. Dis. Obst. Gynecol.*, 2003, 11, 139-145.
10. Rozenfeld, C., Martinez, R., Seabra, S., Sant'anna, C., Gonçalves, J., G., Bozza, M., Moura-Neto, V. and De Souza, W., *Toxoplasma gondii* prevents neuron degeneration by interferon-gamma-activated microglia in a mechanism involving inhibition of inducible nitric oxide synthase and transforming growth factor-beta1 production by infected microglia. *American J. Pathol.*, 2005, 167, 1021–1031.
11. Fond, G., Capdevielle, D., Macgregor, A., Attal, J., Larue, A., Brittner, M., Ducasse, D. and Boulenger, J., P., *Toxoplasma gondii*: a potential role in the genesis of psychiatric disorders. *Encephale.*, 2013, 39, 38-43. [Article in French]
12. Fallahi, Sh., Seyyed Tabaei, S., J., Pournia, Y., Zebardast, N. and Kazemi, B., Comparison of loop-mediated isothermal amplification (LAMP) and nested-PCR assay targeting the RE and B1 gene for detection of *Toxoplasma gondii* in blood samples of children with leukaemia. *Diag. Microbiol. Infect. Dis.*, 2014, 79, 347–354.
13. Arab-Mazar, Z., Fallahi, Sh., Koochaki, A., Haghighi, A. and Seyyed Tabaei, S., J., Immunodiagnosis and molecular validation of *Toxoplasma gondii*-recombinant dense granular (GRA) 7 protein for the detection of toxoplasmosis in patients with cancer. *Microbiologic. Res.*, 2016, 183, 53–59.
14. Henriquez, S., A., Brett, R., Alexander, J., Pratt, J. and Roberts, C., W., Neuropsychiatric Disease and *Toxoplasma gondii* infection. *Neuroimmunomodul.*, 2009, 16, 122–133..



15. Miman, O., Kusbeci, O., Y., Aktepe, O., C. and Cetinkaya, Z., The probable relation between *Toxoplasma gondii* and Parkinson's disease. *Neurosci. Letter.*, 2010, 475, 129–131.
16. Kusbeci, O., Y., Miman, O., Yaman, M., Aktepe, O., C. and Yazar, S., Could *Toxoplasma gondii* have any role in Alzheimer disease? *Alzheimer Dis. Associat. Disord.*, 2011, 25, 1–3.
17. Alvarado-Esquivel, C., Urbina-Álvarez, J., D., Estrada-Martínez, S., Torres-Castorena, A., Molotla-de-León, G., Liesenfeld, O. and Dubey, J., P., *Toxoplasma gondii* infection and schizophrenia: a case control study in a low *Toxoplasma* seroprevalence Mexican population. *Parasitol. Int.*, 2011, 60, 151-155.
18. El-Sahn, A., A., Shatat, H., Z. and Ghitany, E., M., Seropositivity of toxoplasmosis in patients with schizophrenia. *J. Egyptian Pub. Health Associat.*, 2005, 80, 509-524.
19. Jung, B., K., Pyo, K., H., Shin, K., Y., Hwang, Y., S., Lim, H., Lee, S., J., Moon, J., H., Lee, S., H., Suh, Y., H., Chai, J., Y. and Shin, E., H., *Toxoplasma gondii* Infection in the Brain Inhibits Neuronal Degeneration and Learning and Memory Impairments in a Murine Model of Alzheimer's Disease. *PLOS ONE*, 2012, 7, e33312.